Chronic opioid use during pregnancy: Maternal and fetal implications

Clinics in Perinatology

Volumn 40, Issue 3, 2013, Pages 337-350

  Stanhope, Todd J ^a   Gill, Lisa A ^a   Rose, Carl ^a  

^a MAYO CLINIC   (United States)

Author keywords

Buprenorphine; Methadone; Narcotic; Opioid; Pregnancy

Indexed keywords

BUPRENORPHINE; ILLICIT DRUG; METHADONE; NARCOTIC ANALGESIC AGENT;

DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG DETOXIFICATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MISUSE; DRUG OVERDOSE; HUMAN; INAPPROPRIATE PRESCRIBING; LOADING DRUG DOSE; MANAGED CARE; MEDICAL PRACTICE; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; PRACTICE GUIDELINE; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PREMATURE LABOR; PREVENTIVE MEDICINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; WITHDRAWAL SYNDROME;

BUPRENORPHINE; METHADONE; NARCOTIC; OPIOID; PREGNANCY;

ANALGESICS, OPIOID; BUPRENORPHINE; FEMALE; HUMANS; INFANT, NEWBORN; METHADONE; NEONATAL ABSTINENCE SYNDROME; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL CARE;

EID: 84882817911     PISSN: 00955108     EISSN: 15579840     Source Type: Journal    
DOI: 10.1016/j.clp.2013.05.015     Document Type: Review

References (61)

1. Herper M. America's most popular drugs. Forbes 2010.
2. Manchikanti L., Helm S., Fellows B., et al. Opioid epidemic in the United States. Pain Physician 2012, 15(Suppl 3):ES9-ES38.
3. Available at:. Accessed January 9, 2013. http://www.justice.gov/dea/druginfo/ds.shtml.
4. Code of Federal Regulations title 21. Available at:. Accessed January 9, 2013. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm%3ffr%3d201.57.
5. Yaksh T.L., Wallace M.S. Opioid analgesics and pain management. Goodman and Gilman's the Pharmacological basis of Therapeutics 2010, 481-536. McGraw-Hill, New York. 12th edition. L. Brunton, B. Chabner, B. Knollman (Eds.).
6. Hoflich A.S., Langer M., Jagsch R., et al. Peripartum pain management in opioid dependent women. Eur J Pain 2012, 16:574-584.
7. Forman R.F., Block L.G. The marketing of opioid prescriptions without prescription over the internet. J Publ Pol Market 2006, 25(2):133-146.
8. Gugelmann H.M., Perrone J. Can prescription drug monitoring programs help limit opioid abuse?. JAMA 2011, 306(20):2258-2259.
9. Paulozzi L.J., Kilbourne E.M., Desai H.A. Prescription drug monitoring programs and death rates from drug overdose. Pain Med 2011, 12(5):747-754.
10. Green T.C., Zaller N., Rich J., et al. Revisiting Paulozzi etal.'s "Prescription drug monitoring programs and death rates from drug overdose". Pain Med 2011, 12(6):982-985.
11. American College of Obstetricians and Gynecologists Opioid abuse, dependence, and addiction in pregnancy. Committee Opinion No. 524. Obstet Gynecol 2012, 119(5):1070-1076.
12. Mitchell J.L. Alcohol and other drug treatment guidelines for pregnant, substance using women. Treatment improvement protocol series 2: pregnant, substance-using women 1995, 14-32. US Department of Health and Human Services, Rockville, Maryland.
13. Swift R.M., Dudley M., DePetrillo P., et al. Altered methadone pharmacokinetics in pregnancy: implications for dosing. JSubst Abuse 1989, 1(4):453-460.
14. DePetrillo P.B., Rice J.M. Methadone dosing and pregnancy: impact on program compliance. Int J Addict 1995, 30(2):207-217.
15. Jansson L.M., Dipietro J.A., Velez M., et al. Maternal methadone dosing schedule and fetal neurobehaviour. JMatern Fetal Neonatal Med 2009, 22(1):29.
16. Drozdick J., Berghella V., Hill M., et al. Methadone trough levels in pregnancy. Am J Obstet Gynecol 2002, 187(5):1184-1188.
17. Kashiwagi M., Arlettaz R., Lauper U., et al. Methadone maintenance program in a Swiss perinatal center: (I): management and outcome of 89 pregnancies. Acta Obstet Gynecol Scand 2005, 84(2):140-144.
18. Liu A.J., Sithamparanathan S., Jones M.P., et al. Growth restriction in pregnancies of opioid-dependent mothers. Arch Dis Child Fetal Neonatal Ed 2010, 95(4):F258-F262.
19. Helmbrecht G.D., Thiagarajah S. Management of addiction disorders in pregnancy. JAddict Med 2008, 2(1):1-16.
20. Committee on Drugs, American Academy of Pediatrics The transfer of drugs and other chemicals into human breast milk. Pediatrics 2001, 108:776-789.
21. Jones H.E., Kaltenbach K., Heil S.H., et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. NEngl J Med 2010, 363(24):2320-2331.
22. Minozzi S., Amato L., Vecchi S., et al. Maintenance agonist treatments for opiate dependent pregnant women. Cochrane Database Syst Rev 2008, (2):CD006318.
23. Alto W.A., O'Connor A.B. Management of women treated with buprenorphine during pregnancy. Am J Obstet Gynecol 2011, 205(4):302-308.
24. Jones H.E., Heil S.H., Baewert A., et al. Buprenorphine treatment of opioid-dependent women: a comprehensive review. Addiction 2012, 107(Suppl 1):5-27.
25. Dashe J.S., Jackson G.L., Olscher D.A., et al. Opioid detoxification in pregnancy. Obstet Gynecol 1998, 92(5):854.
26. Ward J., Hall W., Mattick R.P. Role of maintenance treatment in opioid dependence. Lancet 1999, 353(9148):221-226.
27. Comer V.G., Annitto W.J. Buprenorphine: a safe method for detoxifying pregnant heroin addicts and their unborn. Am J Addict 2004, 13:317-318.
28. Annitto W.J. Detoxification with buprenorphine of a pregnant heroin addict. Am J Addict 2000, 9:92-93.
29. Substance Abuse and Mental Health Services Administration Results from the 2011 National Survey on drug use and health: summary of National Findings 2012, NSDUH Series H-44, HHS Publication No. (SMA) 12-4713, Substance Abuse and Mental Health Services Administration, Rockville (MD).
30. Doyon S. Chapter 180. Opioids. Tintinalli's emergency medicine 2011, The McGraw-Hill Companies, Inc, New York. 7th edition. J.E. Tintinalli, S. Stapczynski, D.M. Clinc (Eds.).
31. Jones H.E., O'Grady K.E., Malfi D., et al. Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes. Am J Addict 2008, 17(5):372-386.
32. Winklbaur B., Jung E., Fischer G. Opioid dependence and pregnancy. Curr Opin Psychiatry 2008, 21(3):255-259.
33. Schempf A.H. Illicit drug use and neonatal outcomes: a critical review. Obstet Gynecol Surv 2007, 62(11):749-757.
34. Broussard C.S., Rasmussen S.A., Reefhuis J., et al. National birth defects prevention study. Maternal treatment with opioid analgesics and risk for birth defects. Am J Obstet Gynecol 2011, 204(4). 314.e1-11.
35. Bell J., Harvey-Dodds L. Pregnancy and injecting drug use. BMJ 2008, 336(7656):1303-1305.
36. Park E.M., Meltzer-Brody S., Suzuki J. Evaluation and management of opioid dependence in pregnancy. Psychosomatics 2012, 53:424-432.
37. Jansson L.M., Dipietro J., Elko A. Fetal response to maternal methadone administration. Am J Obstet Gynecol 2005, 193(3 Pt 1):611-617.
38. Jones H.E., Finnegan L.P., Kaltenbach K. Methadone and buprenorphine for the management of opioid dependence in pregnancy. Drugs 2012, 72(6):747-757.
39. Ramirez-Cacho W.A., Flores S., Schrader R.M., et al. Effect of chronic maternal methadone therapy on intrapartum fetal heart rate patterns. JSoc Gynecol Investig 2006, 13(2):108-111.
40. Kellogg A., Rose C.H., Harms R.H., et al. Current trends in narcotic use in pregnancy and neonatal outcomes. Am J Obstet Gynecol 2011, 204(3):259.e1-259.e4.
41. Rajani A.K., Chitkara R., Halamek L.P. Delivery room management of the Newborn. Pediatr Clin North Am 2009, 56(3):515-535.
42. Jansson L.M., Velez M. Neonatal abstinence syndrome. Curr Opin Pediatr 2012, 24(2):252-258.
43. Pizarro D., Habli M., Grier M., et al. Higher maternal doses of methadone does not increase neonatal abstinence syndrome. JSubst Abuse Treat 2011, 40(3):295-298.
44. Dashe J.S., Sheffield J.S., Olscher D.A., et al. Relationship between maternal methadone dosage and neonatal withdrawal. Obstet Gynecol 2002, 100(6):1244-1249.
45. Hudak M.L., Tan R.C., Committee on Drugs, Committee on Fetus and Newborn Neonatal drug withdrawal. Pediatrics 2012, 129:e540-e560.
46. Patrick S.W., Schumacher R.E., Benneyworth B.D., et al. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA 2012, 307(18):1934-1940.
47. Handal M., Engeland A., Rønning M., et al. Use of prescribed opioid analgesics and co-medication with benzodiazepines in women before, during, and after pregnancy: a population-based cohort study. Eur J Clin Pharmacol 2011, 67(9):953-960.
48. Hunt R.W., Tzioumi D., Collins E., et al. Adverse neurodevelopmental outcome of infants exposed to opiate in-utero. Early Hum Dev 2008, 84(1):29-35.
49. Walhovd K.B., Watts R., Amlien I., et al. Neural tract development of infants born to methadone-maintained mothers. Pediatr Neurol 2012, 47(1):1-6.
50. Mactier H. The management of heroin misuse in pregnancy: time for a rethink?. Arch Dis Child Fetal Neonatal Ed 2011, 96(6):F457-F460.
51. Deakin C.D., Morrison L.J., Morley P.T., et al. 2010 International consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations. Resuscitation 2010, 81S:e93-e174.
52. Vanden Hoek T.L., Morrison L.J., Shuster M., et al. Circulation 2010, 122:S829-S861.
53. Kosten T.R. Chapter 393. Opioid drug abuse and dependence. Harrison's principles of internal medicine 2012, McGraw-Hill Companies, Inc, New York. 18th edition. D.L. Longo, A.S. Fauci, D.L. Kasper (Eds.).
54. Mégarbane B., Buisine A., Jacobs F., et al. Prospective comparative assessment of buprenorphine overdose with heroin and methadone: clinical characteristics and response to antidotal treatment. JSubst Abuse Treat 2010, 38(4):403-407.
55. Paulozzi L., Baldwin G., Franklin G., et al. CDC grand rounds: prescription drug overdoses-a U.S. epidemic. MMWR Morb Mortal Wkly Rep 2012, 61(1):10-13.
56. Lembke A. Why doctors prescribe opioids to known opioid abusers. NEngl J Med 2012, 367(17):1580-1581.
57. Okie S. Aflood of opioids, a rising tide of deaths. NEngl J Med 2010, 363(21):1981-1985.
58. US Food and Drug Administration Risk Evaluation and Mitigation Strategy (REMS) for Extended-Release and Long-Acting Opioids. Retrieved from the FDA website:. Accessed December 17, 2012. http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm309742.htm.
59. Nelson L.S., Perrone J. Curbing the opioid epidemic in the United States: the risk evaluation and mitigation strategy (REMS). JAMA 2012, 308(5):457-458.
60. DEA Drug Scheduling. Retrieved from the United States Drug Enforcement Agency website:. Accessed December 17, 2012. http://www.justice.gov/dea/druginfo/ds.shtml.
61. Howland R.H. Categorizing the safety of medications during pregnancy and lactation. JPsychosoc Nurs Ment Health Serv 2009, 47(4):17-20.